-+ 0.00%
-+ 0.00%
-+ 0.00%

ROIVANT ANNOUNCES FDA APPROVAL OF LISRAYA™ (BREPOCITINIB) FOR ADULTS WITH DERMATOMYOSITIS; NOW AVAILABLE IN THE U.S.

Reuters·08/27/2026 19:29:02

Please log in to view news